Related to Ventana, Advanced Cell Diagnostics Ally for Automated RNA In Situ Hybridization Assays

• Proteome Sciences Inks Deal with Axela to Develop Brain-Damage Biomarker Assays
  
• Ventana to Work on Companion Diagnostic for Clovis’ Phase II Lipid-Conjugated Gemcitabine
  
• FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test
  
• AltheaDx and Compendia Launch Breast Cancer Segregation Panel
  
• Takeda Pays Zinfandel $9M Up Front for Rights to Predictive AD Biomarker
  
• Qiagen Takes Minority Slice of Alacris to Access Biomarker Technology
  
• Ventana Licenses Cell Signaling’s EGFR IP and Antibodies for Tissue-Based IVDs
  
• Researchers Claim That Measuring Seven Proteins Could Help Anticipate Melanoma Relapse
  
• Metamark and Definiens Partner to Develop Tissue-Based Cancer Diagnostics
  
• OvaGene Licenses Moffitt’s miRNA Markers for Cancer Assays
  
• Lineagen, Fast Forward Team Up to Develop MS Tests
  
• Aeterna Zentaris Taps Ventana for Companion Diagnostic to LHRH-Receptor Targeting Drug
  
• Ventana Joins Pfizer, CST in Developing Companion Dx for Personalized Cancer Treatment
  
• Seattle, Millennium Tap Ventana to Develop Companion Dx for Lymphoma Drug
  
• Ventana Licenses Gen-Probe IP for Measuring ERG Protein in Prostate Cancer
  
• Ventana Licenses BRAF V600E Mutation Antibody for Diagnostic Purposes
  
• Affymetrix, Leica Forge Pact for Single-Copy RNA ISH Tissue Assay for Research Use
  
• Trillium Licenses Cell-Free DNA Biomarker for Sepsis Dx
  
• Lab21, IntegraGen Aim to SPARQ New Cancer Diagnostic
  
• Definiens to Develop Image Analysis Application for ACD